Cellipont Bioservices Expands CDMO Partnership with CellVax for Personalised Cancer Immunotherapies

• Cellipont Bioservices and CellVax Therapeutics have expanded their partnership to include cGMP manufacturing and technology transfer for personalised cancer immunotherapies.

• The agreement supports ongoing clinical development of FK-PC101 and the planned advancement of FK-GI101 for gastrointestinal cancers.

Cellipont Bioservices, a cell therapy CDMO, has announced an expanded collaboration with CellVax Therapeutics Inc., a clinical-stage biotechnology company developing personalised immunotherapies. The agreement builds on existing work around FK-PC101, currently in Phase II trials for high-risk prostate cancer, and will now include support for FK-GI101.

The expanded partnership will cover cGMP manufacturing, drug substance and product technology transfer, and GMP facility readiness. FK-GI101 is an autologous cell-based immunotherapy for gastric, pancreatic, and colon cancer. It uses a patient’s tumour cells, modified to express MHC Class II molecules, to boost immune recognition before being inactivated and re-administered.

Darren Head, CEO of Cellipont Bioservices, commented, “We’re proud to deepen our collaboration with CellVax as they bring their pioneering platform into new and challenging indications.”

CellVax CEO Fernando Kreutz noted that the extended partnership is key to scaling their platform and advancing new therapies into the clinic. The two companies aim to accelerate clinical progress for cancers with limited treatment options by leveraging Cellipont’s manufacturing expertise and infrastructure.